RxDoctor Payments Data

Elias Belezos, MD

Internal Medicine · Southbridge, MANPI 1205819109

Payments from drug & device makers

$938in general payments, 2019–2025

Across 59 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$140
  • GSK$140
  • Lilly USA, LLC$124
  • AstraZeneca$104
  • Boehringer Ingelheim$83
  • Johnson & Johnson$71
  • plus $276 from 10 others

What the payments were for

  • Food & beverage$938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$938 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$101,093
Medicare patients
339
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$136,436
JardianceEmpagliflozin60$76,552
OzempicSemaglutide61$75,706
TrulicityDulaglutide44$50,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$37,511
MounjaroTirzepatide34$36,925
Breo ElliptaFluticasone/Vilanterol55$24,069
FarxigaDapagliflozin Propanediol17$18,261
LinzessLinaclotide17$16,874
XareltoRivaroxaban18$15,023
JanuviaSitagliptin Phosphate14$11,194
Atorvastatin Calcium651$9,192
OxycontinOxycodone Hcl14$7,864
Albuterol Sulfate HfaAlbuterol Sulfate226$7,488
Lidocaine57$6,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$62$138,651124 claims
Lilly USA, LLCTrulicity, Mounjaro$124$86,94078 claims
Boehringer IngelheimJardiance$83$76,55260 claims
Novo NordiskOzempic$17$75,70661 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$140$69,682120 claims
AstraZenecaFarxiga, Brilinta, Symbicort$104$27,14240 claims
Johnson & JohnsonXarelto$71$15,02318 claims
MerckJanuvia$15$11,19414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Southbridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →